<DOC>
	<DOCNO>NCT00321230</DOCNO>
	<brief_summary>Monocentric , cleanse evaluation pilot study patient undergo colonoscopy .</brief_summary>
	<brief_title>Clinical Evaluation New Reduced Volume Bowel Preparation</brief_title>
	<detailed_description>Open prospective pilot monocentric phase II clinical trial evaluate therapeutic efficacy new `` Low Dose Bowel Prep '' formulation gut cleanse prior colonoscopy . Thirty patient admit hospital ( inpatient ) plan undergo complete colonoscopy gut cleanse `` Low Dose Bowel Prep '' use one-step intake mode .</detailed_description>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Polyethylene glycol 3350</mesh_term>
	<criteria>male female , inpatient 18 65 year old indication complete colonoscopy patient 's write informed consent must obtain prior inclusion willing able complete entire procedure comply study instruction ileus toxic megacolon intestinal obstruction perforation know G6PD insufficiency history colonic surgery ischaemic cardiovascular disease untreated uncontrolled arterial hypertension ( max &gt; 170mmHg , min &gt; 100mmHg ) renal insufficiency ( create 45Âµmol/l ) abnormal laboratory value ( clinically significant ) sodium , potassium , chloride , creatinine hematocrit cirrhosis liver ( ChildPugh grade B C ) females pregnant , nurse planning pregnancy . Females child bear potential use reliable method contraception . concurrent participation investigational drug study participation within 30 day study entry subject condition situation investigator opinion may put subject significant risk , may confound study result may interfere significantly</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Colon cleansing</keyword>
</DOC>